Foundation Medicine

Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care

What You Should Know:  – Foundation Medicine (FMI) announced today a partnership to integrate its comprehensive genomic testing services into Epic’s electronic medical record (EMR) platform, making it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to develop …

Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care Read More »

Foundation Medicine Integrates Genomic Profiling with Flatiron Health’s EMR

What You Should Know: – Foundation Medicine (FMI) announced today it will begin integrating with Flatiron Health and other electronic medical record (EMR) systems to make it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to quickly and efficiently develop personalized treatment …

Foundation Medicine Integrates Genomic Profiling with Flatiron Health’s EMR Read More »

Getting the right data to doctors is next hurdle for precision medicine

The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.

String of FDA approvals gives momentum to liquid biopsies

Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.

Foundation Medicine’s FoundationOne CDx Receives the US FDA’s Approval as a CDx for Vitrakvi (larotrectinib)

Shots: The US FDA approved FoundationOneCDx to be used as a CDx for Vitrakvi (larotrectinib) to identify patients with NTRK fusions across all solid tumors. The genomic test is currently approved as a CDx for 20+ therapies The FoundationOne CDx is the tissue-based CGP test approved to detect NTRK1/2/3 fusions across all solid tumor types …

Foundation Medicine’s FoundationOne CDx Receives the US FDA’s Approval as a CDx for Vitrakvi (larotrectinib) Read More »

Foundation Medicine to launch liquid biopsy companion diagnostic following FDA approval

The company announced Wednesday the FDA approval of its liquid biopsy test, the second to win an agency nod in less than a month, saying it would launch the product on Friday. The FDA acquired the first ever liquid biopsy companion diagnostic, Guardant Health’s Guardant360 CDx, on Aug. 10.